Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis Economic Evaluation of Infliximab in UC Patients
Iranian Journal of Pharmaceutical Sciences,
مجلد 12 عدد 4 (2016),
1 مهر 2016
,
الصفحة 33-42
https://doi.org/10.22037/ijps.v12.40711
الملخص
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients were individuals with moderate to severe UC that are resistant to conventional treatments. Remission rate, clinical response, and surgery were selected as clinical outcomes. For estimating QALY, utility value related to each state, was derived form published paper. We also estimated associated probabilities by using patients ’medical records and specialists’ opinion. Costs of treatment such as Physician visit fee, laboratory tests, hospitalizations, surgery, and drugs were estimated based on the public sector tariffs and drug price list set by pricing committee of food and drug administration. Infliximab costs at dosage of 5 mg /kg were considered for UC patients with average weight of 75 kilogram. Incremental Cost-Effectiveness Ratio (ICER) of infliximab treatment in UC patients were 240,903 USD dollars per QALY gained, compared with conventional treatments. According to recommendation of World Health Organization for choosing cost-effective intervention, interventions with relative cost-effectiveness value less than 3 times of Gross Domestic Production (GDP) per capita, are cost–effective. Our result showed that the ICER value of infliximab is approximately 51 times of Iran’s local GDP per capita, in 2014 – i.e. more than 3 time GDP per capita. Thus, for UC patients, our finding indicates that infliximab is not a cost- effective treatment.
- Conventional treatments
- Cost-effectiveness analysis
- Economic evaluation
- Incremental cost-effectiveness ratio
- Infliximab
- Ulcerative colitis.
كيفية الاقتباس
المراجع
[2] Ochsenkühn T, Sackmann M, Göke B. [Inflammatory bowel diseases (IBD)--critical discussion of etiology, pathogenesis, diagnostics, and therapy]. Der Radiologe. (2003) 43(1):1-8.
[3] Kathleen A. Head ND JSJMA. Inflammatory bowel disease part I: ulcerative colitis–pathophysiology and conventional and alternative treatment options. Altern Med Rev (2003) 8(3):247-83.
[4] Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet (2012) 380(9853):1606-19.
[5] Nedelciuc O, Pintilie I, Dranga M, Mihai C, Prelipcean CC. Quality of life in patients with ulcerative colitis. Rev Med Chir Soc Med Nat Iasi (2012) 116(3):756-60.
[6] Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14(4):554-65.
[7] Gibson PR, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. J Crohns Colitis (2014) 8(7):598-606.
[8] Loftus EV. Epidemiology of Inflammatory Bowel Disease. GI Epidemiology: Diseases and Clinical Methodology . John Wiley & Sons, Ltd (2014) p. 273-84.
[9] Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. (2012) 27(8):1266-80.
[10]Shayesteh AA, Saberifirozi M, Abedian S, Sebghatolahi V. Epidemiological, Demographic, and Colonic Extension of Ulcerative Colitis in Iran: A Systematic Review. Middle East J Dig Dis. (2013) 5(1):29-36.
[11] Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther (2010)31(7):693-707.
[12] Garud S, Peppercorn MA. Ulcerative Colitis: Current Treatment Strategies and Future Prospects. Therap Adv Gastroenterol (2009) 2(2):99-108.
[13] Lee JK, Tang DH, Mollon L, Armstrong EP. Cost-effectiveness of biological agents used in ulcerative colitis. Best Pract Res Clin Gastroenterol (2013) 27(6):949-60.
[14] Samaan MA, Bagi P, Vande Casteele N, D’Haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterol Clin North Am (2014) 43(3):479-94.
[15] Stidham RW, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther (2014) 39(7):660-71.
[16] Reinisch W, et al. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. J Crohns Colitis 2012 6(2):248-58.
[17] Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther (2008) 30(2):223-30.
[18] Zhou Z, Dai C, Liu WX. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Hepatogastroenterology (2015) 62(138):309-18.
[19] Bressler B, et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol (2008) 22(11):937-40.
[20] Chaudhary MA, Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biol Ther (2013) 3(1):45-60.
[21] Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ (2010) 11(1):67-76.
[22] Basson MD. Ulcerative Colitis Treatment & Management 2014 (Accessed sep 14, 2015). Available from:URL: http://emedicine.medscape.com/article/183084-treatment.
[23] de Vries HS, van Oijen MGH, Driessen RJB, de Jong EMGJ, Creemers MCW, Kievit W, de Jong DJ. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol. (2011) 71(1):7-19.
[24] US Food and Drug Administration: Infliximab Product Approval Information - Licensing Action, (Accessed Sep 20, 2015). Available from:URL:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Ap provalApplications/TherapeuticBiologicApplications/ucm093327.htm
[25] Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technol Assess (2010) 14 Suppl 1.
[26] National Institute for Health and Clinical Excellence (NICE). Ifliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262). (Accessed Sep 1, 2015). Available from: URL: https://www.nice.org.uk/guidance/ta329
[27] Hovde Ø, Huppertz-Hauss G, Høivik M, Moum B. Clinical Course, Treatment Strategies, Social and Economic Impact of Ulcerative Colitis: An Overview. Austin J Gastroenterol. (2014) 1(4):1017.
[28] Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 53(suppl 5):v1-v16.
[29] Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol (1999) 149(10):916-24.
[30] Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV, Jr. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis (2013) 19(9):2001-10.
[31] Jess T, Gamborg M, Munkholm P, Sorensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol (2007) 102(3):609-17.
[32] Arseneau KO, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol (2006) 4(9):1135-42.
[33] Weinstein MC, Torrance G, McGuire A. QALYs: The Basics. Value Health (2009)12:S5-S9.
[34] Assasi N BG, Xie F, Gaebel K, Marshall J, Irvine EJ, Giacomini M, Robertson , D CK, Hopkins R, Goeree R. Anti-TNF-α drugs for refractory inflammatory bowel disease: Clinical- and cost-effectiveness analyses. Technology report number 120. DARE (2009).
[35] Lopez A, Ford AC, Colombel J-F, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis )2015) 47(5):356-64.
[36] Ung V, et al. Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis. Clin Gastroenterol Hepatol (2014) 12(11):1871-8.e8.
[37] Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost effectiveness and resource allocation.Cost Eff Resour Alloc (2009) 7:20.
[38] Organization. WH. Cost effectiveness and strategic planning (WHO-CHOICE), cost effectiveness threshold value. (Accessed Aug 20, 2015). Available from: http://www.who.int/choice/costs/CER_thresholds/en/
- الملخص المشاهدات: 104 الأوقات
- IJPS_Volume 12_Issue 4_Pages 33-42 (English) التنزيلات: 19 الأوقات